发布求助
文献互助 智能选刊 最新文献

Expert Opinion on Biological Therapy最新文献

筛选
英文 中文
The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process. 美国食品和药物管理局批准用于治疗杜氏肌营养不良症的 delandistrogene moxeparvovec-rokl：对证据和监管程序的批判性审查。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-20 DOI: 10.1080/14712598.2024.2394477
Mehul Bhattacharyya, Larry E Miller, Anna L Miller, Ruemon Bhattacharyya
{"title":"The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process.","authors":"Mehul Bhattacharyya, Larry E Miller, Anna L Miller, Ruemon Bhattacharyya","doi":"10.1080/14712598.2024.2394477","DOIUrl":"10.1080/14712598.2024.2394477","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"869-871"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future of aptamers in cancer diagnosis, prognosis and treatment. 适配体在癌症诊断、预后和治疗中的未来。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-03 DOI: 10.1080/14712598.2024.2399148
Jazmine Arévalo, Adrian Gabriel Torres
{"title":"The future of aptamers in cancer diagnosis, prognosis and treatment.","authors":"Jazmine Arévalo, Adrian Gabriel Torres","doi":"10.1080/14712598.2024.2399148","DOIUrl":"10.1080/14712598.2024.2399148","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"873-877"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-17 inhibitors in axial spondyloarthritis. An overview. 轴性脊柱关节炎中的 IL-17 抑制剂。综述。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI: 10.1080/14712598.2024.2394472
Eric Toussirot, Renaud Felten
{"title":"IL-17 inhibitors in axial spondyloarthritis. An overview.","authors":"Eric Toussirot, Renaud Felten","doi":"10.1080/14712598.2024.2394472","DOIUrl":"10.1080/14712598.2024.2394472","url":null,"abstract":"<p><strong>Introduction: </strong>The therapeutic armamentarium for spondyloarthritis has expanded considerably in recent years, and there is growing evidence to support the increasing use of IL-17 inhibitors (IL-17i) in axial spondyloarthritis (axSpA).</p><p><strong>Areas covered: </strong>This literature review provides an update on the role of IL-17 in the pathogenesis of axSpA, efficacy and safety from clinical trials and real-life studies on the use of IL17i in axSpA. We also review the impact of extra-musculoskeletal manifestations on the decision to treat with IL17i and the efficacy of IL17i on structural progression.</p><p><strong>Expert opinion: </strong>There are still some unanswered questions concerning the use of IL-17i in axSpA in clinical practice such as their respective place in the management of axSpA compared to TNFα inhibitors (TNFi). Their main differences rely on their specific efficacy in extra-articular manifestations such as psoriasis, uveitis, and inflammatory bowel diseases leading to the choice of the best treatment in a given patient. Regarding their real impact on structural progression, the rate of progression under IL-17i appears to be low and presumably similar to TNFi. One final question is the advantage of blocking the two IL-17 isoforms A and F compared to the single inhibition of IL-17A.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"917-932"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1080/14712598.2024.2390778
{"title":"Correction.","authors":"","doi":"10.1080/14712598.2024.2390778","DOIUrl":"10.1080/14712598.2024.2390778","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"993"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement. 多发性骨髓瘤的 T 细胞重定向双特异性抗体治疗：T 细胞持续参与的现有知识和未来策略。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 DOI: 10.1080/14712598.2024.2397436
Marise R Heerma van Voss, Remco J Molenaar, Charlotte L B M Korst, Imke H Bartelink, Serena R Baglio, Sandy Kruyswijk, Maaike de Ruijter, Sonja Zweegman, Maria T Kuipers, Niels W C J van de Donk
{"title":"T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement.","authors":"Marise R Heerma van Voss, Remco J Molenaar, Charlotte L B M Korst, Imke H Bartelink, Serena R Baglio, Sandy Kruyswijk, Maaike de Ruijter, Sonja Zweegman, Maria T Kuipers, Niels W C J van de Donk","doi":"10.1080/14712598.2024.2397436","DOIUrl":"10.1080/14712598.2024.2397436","url":null,"abstract":"<p><strong>Introduction: </strong>T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation antigen (BCMA) or G-protein - coupled receptor class C group 5 member D (GPRC5D), are efficacious new agents for the treatment of patients with relapsed or refractory MM.</p><p><strong>Areas covered: </strong>This review discusses the pharmacokinetic properties, efficacy, and safety profile of T-cell redirecting BsAbs in MM, with a special focus on their optimal dosing schedule, resistance mechanisms and future strategies to enhance efficacy, reduce toxicity, and maximize duration of response.</p><p><strong>Expert opinion: </strong>To further improve the efficacy of BsAbs, ongoing studies are investigating whether combination therapy can enhance depth and duration of response. An important open question is also to what extent response to BsAbs can be improved when these agents are used in earlier lines of therapy. In addition, more evidence is needed on rational de-intensification strategies of BsAb dosing upon achieving a sufficient response, and if (temporary) treatment cessation is possible in patients who have achieved a deep remission (e.g. complete response or minimal residual disease-negative status).</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"889-901"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia. 对 exagamglogene autotemcel 治疗镰状细胞病和输血依赖型β-地中海贫血症的评估。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1080/14712598.2024.2399134
Rupert Handgretinger, Markus Mezger
{"title":"An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.","authors":"Rupert Handgretinger, Markus Mezger","doi":"10.1080/14712598.2024.2399134","DOIUrl":"10.1080/14712598.2024.2399134","url":null,"abstract":"<p><strong>Introduction: </strong>Sickle cell disease is the most common hereditary hemoglobinopathy followed by beta-thalassemia. Until recently, allogeneic stem cell transplantation was the only curative approach. Based on the Crispr-Cas9-technology enabling targeting specific genes of interest, fetal hemoglobin which is normally shut-off after birth can be switched on and sufficient levels can alleviate symptoms in sickle cell disease and avoid transfusions in beta-thalassemia. Two first-in-human clinical studies in sickle cell disease and beta-thalassemia aiming to increase the level of fetal hemoglobin by using Crispr-Cas9 to modify autologous hematopoietic stem cells in patients aged 12-35 years have proved safety and efficacy and have shown promising clinical outcomes.</p><p><strong>Areas covered: </strong>The paper summarizes the outcome of the results of the two recently published clinical studies and compares them with the other available curative approaches.</p><p><strong>Expert opinion: </strong>Based on the currently available safety and efficacy data of the two published clinical results on gene therapy with Crispr-Cas9 modified autologous stem cells (exagamglogene autotemcel), it can be anticipated that this approach will add significantly to the therapeutic options for patients with sickle cell disease and beta-thalassemia and can be considered for all patients above 12 years of age independent of a suitable allogeneic stem cell donor.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"883-888"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1080/14712598.2024.2388405
{"title":"Correction.","authors":"","doi":"10.1080/14712598.2024.2388405","DOIUrl":"10.1080/14712598.2024.2388405","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"i"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer. 复发性和晚期转移性宫颈癌的新兴生物疗法综述。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-29 DOI: 10.1080/14712598.2024.2373320
Virginia E Fontenot, Alex Francoeur, Krishnansu S Tewari
{"title":"Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer.","authors":"Virginia E Fontenot, Alex Francoeur, Krishnansu S Tewari","doi":"10.1080/14712598.2024.2373320","DOIUrl":"10.1080/14712598.2024.2373320","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"709-713"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-acting delivery and therapies for neovascular age-related macular degeneration. 新生血管性老年黄斑变性的长效给药和疗法。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-22 DOI: 10.1080/14712598.2024.2374869
Lucas W Rowe, Thomas A Ciulla
{"title":"Long-acting delivery and therapies for neovascular age-related macular degeneration.","authors":"Lucas W Rowe, Thomas A Ciulla","doi":"10.1080/14712598.2024.2374869","DOIUrl":"10.1080/14712598.2024.2374869","url":null,"abstract":"<p><strong>Introduction: </strong>Neovascular age-related macular degeneration (nAMD) represents a leading cause of severe visual impairment in individuals over 50 years of age in developed nations. Intravitreal anti-vascular endothelial growth factor (VEGF) injections have become the standard of care for treating nAMD; however, monthly or bimonthly dosing represents significant time and cost burden due to the disease's chronic nature and limited medication half-life.</p><p><strong>Areas covered: </strong>This review summarizes innovative therapeutics and delivery methods for nAMD. Emerging methods for extended drug delivery include high molar concentration anti-VEGF drugs, intravitreal sustained-release polymers and devices, reservoirs for intravitreal delivery, suprachoroidal delivery of small molecular suspensions and gene therapy biofactories. In addition to VEGF-A, therapies targeting inhibition of VEGF-C and D, the angiopoetin-2 (Ang-2)/Tie-2 pathway, tyrosine kinases, and integrins are reviewed.</p><p><strong>Expert opinion: </strong>The evolving therapeutic landscape of nAMD is rapidly expanding our toolkit for effective and durable treatment. Recent FDA approvals of faricimab (Vabysmo) and high-dose aflibercept (Eylea HD) for nAMD with potential extension of injection intervals up to four months have been promising developments for patients and providers alike. Further research and innovation, including novel delivery techniques and pharmacologic targets, is necessary to validate the efficacy of developing therapeutics and characterize real-world outcomes, demonstrating promise in expanding treatment durability.</p>","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"799-814"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The nail in psoriatic arthritis: new insights into prognosis and treatment. 银屑病关节炎的指甲：预后和治疗的新见解。
IF 3.6 3区 医学
Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1080/14712598.2024.2385020
Rubén Queiro, Sara Alonso, Jose A Pinto-Tasende
{"title":"The nail in psoriatic arthritis: new insights into prognosis and treatment.","authors":"Rubén Queiro, Sara Alonso, Jose A Pinto-Tasende","doi":"10.1080/14712598.2024.2385020","DOIUrl":"10.1080/14712598.2024.2385020","url":null,"abstract":"","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"715-717"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信